Kempner Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Kempner Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-18,935	Closed	-$79K	–	51
2018 Q3	$79K	Hold	18,935	–	–	0.05%	47
2018 Q2	$73K	Hold	18,935	–	–	0.05%	64
2018 Q1	$120K	Hold	18,935	–	–	0.08%	56
2017 Q4	$153K	Hold	18,935	–	–	0.1%	58
2017 Q3	$217K	Sell	18,935 -1	-0%	-$11	0.14%	52
2017 Q2	$185K	Hold	18,936	–	–	0.12%	57
2017 Q1	$459K	Buy	+18,936	New	+$474K	0.31%	41

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kempner Capital Management's MACK Position: Q4 2018 in Review

Kempner Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2018, closing a stake of 18,935 shares — an estimated $79K sold.

Kempner Capital Management first reported a position in MACK in Q1 2017 and held it in 7 quarters. The position peaked at $459K in Q1 2017. 56 funds tracked by Wall St. Rank hold MACK as of Q4 2018.

Kempner Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Kempner Capital Management sold 18,935 Merrimack Pharmaceuticals, Inc. shares in Q4 2018, an estimated $79K.
Kempner Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2017 and held it in 7 quarters.
Kempner Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $459K in Q1 2017.
56 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2018.

Based on Kempner Capital Management's 13F filing for Q4 2018, filed 9 Jan 2019.